Breast cancer treatment currently requires the
joint efforts of a multidisciplinary team to effectively combine
chemotherapy,
hormone therapy, biological agents,
surgery and
radiation therapy when needed. To develop such a
treatment plan, it is important to know the benefits as well as the potential
toxic effects of each
therapy. Thus, many
patients with early
breast cancer complain of collateral adverse events such as
fatigue,
nausea,
vomiting, loss of
libido,
hot flashes, night
sweats or neuropathy due to the complex
therapies they are receiving. To date, the
treatment of such symptoms is an important issue that greatly
affects the
quality of life of these
patients. In this
review, we
report the content of a multi-expert meeting where the
incidence of and medical approach to some of the most common adverse events encountered during the
treatment of
patients with early
breast cancer were analysed (AU)